Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes ...

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 milli ...
ZAWYA

Dubai to host ‘The Microbiome Revolution: A global symposium on science, healthcare and investment

Leading event to bridge research, clinical adoption, and investment in microbiome-enabled health hosted by CE-Ventures, the ...